Cleavable esters for nanocarrier-based cancer therapy
US11633485B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2018 |
| Grant date | Apr 25, 2023 |
| Priority date | — |
| Expiry date | Dec 21, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A co-drug according to Formula (I) or Formula (II) is provided, R—X—NH—CO—CO—OR1 (I)R—X—CO—O—CH2—CO—OR1 (II) wherein R is a tocol moiety, a tocol analog moiety, or a capsaicinoid moiety; X is a direct bond or a linking group; and OR1 is the residue of an anticancer or antirestenotic agent bearing at least one hydroxyl group by which the CO—OR1 ester linkage is formed. Nanoparticles that include the abovementioned co-drug are also provided, as well as a method of treating a cancer patient that includes administering an effective amount of the co-drug or nanoparticles.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.